Helicobacter eradication therapy in Chronic Obstructive Pulmonary Disease: A pilot,randomised, double blinded, placebo controlled trial - COPDHP
Phase 1
- Conditions
- Chronic Obstructive Airways Disease: Defined as a consistent clinical picture with evidence of airflow obstruction (FEV1 < 70%, FEV1/FVC Ratio <70%, with no evidence of reversibility in FEV1 after 200 micrograms of inhaled salbutamol (<15%, or if FEV1 <1 litre, <200 ml improvement)
- Registration Number
- EUCTR2006-005382-19-GB
- Lead Sponsor
- niversity Hospitals of Leicester NHS Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with Chronic Obstructive Airways Disease ( see E.1 for definition)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Age < 18 years
Penicillin allergy
Severe dyspepsia ( at least weekly symptoms either on or off medications)
Patients on PPI who would be unable to stop them for the duration of the study
Patients on long term antibiotics
Patients receiving antibiotics in the 4 weeks prior to start of the study
Patients with liver or kidney disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method